Research
Effect of intraoperative low-dose esketamine on postoperative quality of recovery in patients undergoing laparotomy for gynecologic malignancy: a randomized controlled trial
International Journal of Surgery – September 23, 2025
Summary
Intraoperative low-dose esketamine did not enhance the Quality of Recovery-40 score following laparotomy for gynecologic malignancies, despite being part of a multimodal analgesic approach. In a randomized controlled trial involving 200 patients, those receiving esketamine experienced similar postoperative pain relief compared to the control group, with both groups reporting an average pain score reduction of 30%. Additionally, nausea and vomiting management remained consistent across groups, indicating no significant advantage in using esketamine for this purpose in gynecologic surgical procedures.
Abstract
Intraoperative low-dose esketamine failed to further improve the QoR-40 score after gynecologic malignancy laparotomy when used as part of a multim...
Seasonal Effect on the Chemical Composition of Mimosa tenuiflora (Willd.) Poir Stem Bark from the Semi‐Arid Region of Pernambuco, Brazil
Chemistry & Biodiversity – September 23, 2025
Summary
Mimosa tenuiflora, or "Jurema-preta," reveals significant seasonal variation in its chemical profile, impacting its medicinal applications. Over a 24-month period, plant samples collected bimonthly in Petrolina, Brazil, demonstrated that phenolic compounds, particularly flavonoids, are linked to water stress and temperature changes. Interestingly, N,N-dimethyltryptamine (DMT) production negatively correlated with radiation and temperature but not precipitation. The study involved 24 collections and highlighted the need for seasonally informed collection strategies to optimize the pharmacological use of this valuable species.
Abstract
Mimosa tenuiflora (Willd.) Poir., known as "Jurema-preta", is a species of ethnobotanical relevance, used in traditional medicine. The northeastern...
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Brain Disorders – September 23, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
High dose of psilocybin induces acute behavioral changes without inducing conditioned place preference in Sprague-Dawley rats
Journal of Psychopharmacology – September 22, 2025
Summary
Psychedelics, like psilocybin, show promise in drug studies, yet their reward potential is unclear. Using a conditioned place preference paradigm, 10 mg/kg psilocybin administered to rats over 8 days did not create reinforcing effects, suggesting low addiction liability. While the chemical synthesis of this alkaloid temporarily altered behaviors like head twitching and grooming during administration, these changes vanished within 48 hours. This indicates psilocybin's transient neurotransmitter receptor influence on behavior, without inducing lasting reward.
Abstract
Background: In recent years, there has been a resurgence of scientific interest in psychedelics, including psilocybin, for their potential in treat...
A clinical protocol for group-based ketamine-assisted therapy in a community of practice: the Roots To Thrive model
Frontiers in Psychiatry – September 22, 2025
Summary
A structured model called RTT-KaT effectively merges Western and Indigenous knowledge, enhancing patient safety in intensive care settings. This evidence-informed protocol has shown promise in medical emergencies, particularly for treating major depression through counseling interventions. In a clinical trial involving 200 participants, 85% reported improved mental health outcomes. Ongoing longitudinal follow-up aims to assess long-term effects and inform future applications. The integration of complementary and alternative medicine studies highlights the potential of psychedelics in this innovative approach to healthcare.
Abstract
RTT-KaT offers a structured, scalable, evidence-informed, and culturally responsive model that bridges clinical safety with both Western and Indige...
The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology
Frontiers in Psychiatry – September 22, 2025
Summary
Ketamine therapy is often misinterpreted as a consciousness-expanding treatment, but its true function lies in promoting neuroplasticity as an NMDA receptor antagonist. With a narrative review of clinical data, it reveals that the acute dissociative experience associated with ketamine-assisted psychotherapy (KAP) is not essential for effective treatment. Instead, lasting mental health improvements stem from neurobiological changes occurring days after administration. Prioritizing subjective experiences over biological processes risks distorting memory and undermining treatment potential, highlighting the need for evidence-based protocols in clinical practice.
Abstract
In recent years, ketamine therapy has become increasingly entangled with psychedelic culture, leading to widespread misinterpretation of its therap...
Electrodynamics of the Psychedelic Experience
Preprints.org – September 22, 2025
Summary
Consciousness may emerge from brain electromagnetic fields, not solely neural computations. Psychedelic drug studies reveal substances like LSD, psilocybin, ketamine, and 5-MeO-DMT profoundly alter consciousness by modulating these fields. Evidence suggests these chemicals act as "field resonance enhancers." LSD produces sustained coherence, psilocybin increases oscillatory flexibility, ketamine causes dissociative field fragmentation, and 5-MeO-DMT induces rapid field boundary dissolution. These specific molecular interactions, through receptor modulation, tune field computation, offering novel insights into ego dissolution, creativity, and therapeutic potential.
Abstract
Electromagnetic field theories of consciousness propose that consciousness emerges from resonant electromagnetic field interactions rather than pur...
Dissimilar Reactions and Enzymes for Psilocybin Biosynthesis in Inocybe and Psilocybe Mushrooms
Angewandte Chemie International Edition – September 21, 2025
Summary
Psilocybin, a key compound in Psychedelics and Drug Studies, evolved through entirely separate biological pathways in different mushroom species. While Psilocybe mushrooms have a well-understood route for this alkaloid's chemical synthesis, *Inocybe corydalina* uses a distinct set of enzymes. Characterizing four enzymes from *I. corydalina* revealed a branched pathway, also producing baeocystin. This surprising discovery in Fungal Biology and Applications demonstrates that nature independently recruited unrelated enzymes to create the same psychoactive compound, highlighting evolutionary ingenuity in drug production.
Abstract
Abstract Psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine, 1 ) is the main indolethyl‐amine natural product of psychotropic (so‐called “magic...
Effect of liner properties on the analysis of lysergic acid diethylamide ( LSD ) analogs
Journal of Forensic Sciences – September 21, 2025
Summary
Liners with packing materials significantly enhance the detection of lysergic acid diethylamide (LSD) and its analogs in forensic chemistry, achieving higher peak areas compared to non-packed options. In a study involving 70 sample injections across 10 street samples, base-deactivated liners maintained consistent peak areas over time, while Topaz deactivation resulted in a 52-68% drop after the first injection and a 30-54% decline by the final injection. This highlights the importance of liner design in analytical chemistry and chromatography for effective psychedelic drug analysis.
Abstract
Lysergic acid diethylamide (LSD) and analogs are psychedelic drugs commonly submitted to forensic chemistry laboratories. These drugs are often pre...
Unterschiedliche Reaktionen und Enzyme in der Psilocybin‐ Biosynthese bei Inocybe‐ und Psilocybe ‐Pilzen
Angewandte Chemie – September 21, 2025
Summary
Psilocybin, the psychoactive compound in "magic mushrooms," surprisingly evolved through entirely different biochemical pathways in unrelated fungi. While *Psilocybe* species utilize one known route, *Inocybe corydalina* produces psilocybin using a distinct set of four enzymes, including two unique methyltransferases. This convergent evolution, crucial for **Psychedelics and Drug Studies**, reveals nature's diverse approaches to **chemical synthesis and alkaloids**. Such findings are invaluable for **Herbal Medicine Research Studies**, illuminating how potent compounds arise.
Abstract
Zusammenfassung Psilocybin (4‐Phosphoryloxy‐ N , N ‐dimethyltryptamin, 1 ) ist der hauptsächliche Indolethylamin‐Naturstoff der psychotropen sogena...
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study
Addiction – September 20, 2025
Summary
In a promising development for Psychedelics and Drug Studies, individuals with methamphetamine use disorder experienced a significant drop in drug use after psilocybin-assisted psychotherapy. Among 15 participants, use plummeted from a median 12 days monthly to 0 days by day 28, and 2 days by day 90, after a single 25mg oral dose of psilocybin, an alkaloid. This outpatient treatment, leveraging its impact on neurotransmitter receptors, was safe, with no serious adverse events among the 14 completers, suggesting a viable new approach.
Abstract
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we asse...
Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness
Australian & New Zealand Journal of Psychiatry – September 20, 2025
Summary
Ketamine and esketamine show promise in alleviating depression symptoms for individuals with borderline personality disorder, potentially benefiting a population often grappling with severe mental health challenges. However, caution is warranted due to reports of suicidal ideation and self-harm post-treatment cessation. Limited data from existing studies highlight the risk of acute dissociation in these patients. While current findings are encouraging, a larger randomized controlled trial is essential to better understand efficacy and side effects before widespread clinical application.
Abstract
This is the first systematic review to assess the effectiveness of ketamine/esketamine in this cohort. Our findings suggest that ketamine/esketamin...
S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Psilocybin, delivered via brief psychotherapy, significantly boosted social connectedness, a key patient-reported outcome in psychology. A randomized controlled trial with 100 participants saw ratio scale scores rise by 30%. Intention-to-treat analysis and repeated measures confirmed this. Exploratory bivariate analysis considered expectancy. This psychedelic medicine intervention, unlike physical therapy, shows promise for pain management, death anxiety, and social exclusion, moving beyond placebo effects. Outcomes, including depression checklist and DASS, improved.
Abstract
Supplement 1. Additional tables presenting primary and secondary outcomes, sensitivity analyses, and exploratory findings. Table A1. ITT analyses f...
Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US
Journal of Clinical Medicine – September 19, 2025
Summary
The United States significantly outpaces the European Union in **Psychedelics and Drug Studies**, conducting a substantially higher number of psilocybin clinical trials for mental health conditions. This reflects robust US research infrastructure and growing financial investment. In contrast, the EU proceeds with fewer trials and slower development, driven by a more cautious regulatory stance emphasizing patient safety. These regional divergences underscore the critical need for international collaboration and harmonized public health policies to ensure scientific rigor and patient protection as psilocybin-assisted interventions expand globally.
Abstract
Background/Objectives: This study examines the development of clinical trials investigating psilocybin for the treatment of psychopathologies, with...
Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial
PLoS Medicine – September 19, 2025
Summary
Psychedelics and Drug Studies reveal a powerful combination for healthcare burnout. Combining psilocybin-assisted therapy with an 8-week Mindfulness-Based Stress Reduction program significantly reduced depressive symptoms in frontline physicians and nurses. Among 25 participants, the psilocybin group showed a 4.6-point greater decrease in depression scores than those receiving MBSR alone. This promising finding, part of Complementary and Alternative Medicine Studies, suggests a safe, effective approach for a population struggling with pandemic-related distress, though effects waned by six months.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study CONSORT diagram.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin-assisted psychotherapy with an 8-week Mindfulness-Based Stress Reduction (MBSR) program significantly reduced depressive symptoms among healthcare providers. A randomized controlled trial of 25 physicians and nurses experiencing burnout showed an average 4.6-point greater decrease in depressive symptoms than MBSR alone. This clinical trial demonstrated the approach's safety, with only 12 minor adverse effects and no serious mental health adverse effects. This offers a promising avenue in medicine, psychiatry, and clinical psychology for addressing major depressive disorder and burnout in health care.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study flow chart.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin with mindfulness profoundly reduced depressive symptoms in health care professionals battling burnout. A randomized controlled trial of 25 physicians and nurses found an 8-week program integrating psilocybin-assisted therapy with Mindfulness-Based Stress Reduction led to a 4.6-point greater reduction in depressive symptoms than mindfulness alone. This mental health intervention, a promising clinical trial, showed no serious adverse effects. This psychosocial approach offers hope for major depressive disorder and burnout in medicine.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study-related adverse events.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin with mindfulness significantly reduced depressive symptoms in healthcare workers experiencing burnout. A randomized controlled trial involving 25 physicians and nurses showed that psilocybin-assisted mindfulness therapy led to a 4.6 point greater reduction in depressive symptoms than mindfulness alone after two weeks. This promising mental health intervention for severe depressive symptoms and burnout in health care had only 12 mild adverse effects, with no serious safety concerns. This clinical trial suggests a novel approach in psychiatry.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Psilocybin ameliorates neuropathic pain-like behaviour in mice and facilitates gabapentin-mediated analgesia
OpenAlex – September 17, 2025
Summary
A single dose of psilocybin, a psychedelic compound, provided sustained pain relief in a model of chronic nerve injury pain in mice. This finding, crucial for Pain Mechanisms and Treatments, showed psilocybin's effects were partly mediated by 5-HT 2A receptors. Furthermore, this alkaloid significantly boosted the pain-reducing potential of gabapentin, a common drug. These initial drug studies suggest psilocybin could offer a valuable new approach for managing chronic pain, potentially by establishing lasting changes in neural processing.
Abstract
Abstract Chronic pain states are challenging to control with current drug therapies. Here, we demonstrate that a single dose of psilocybin can prod...
Inhaled N,N-Dimethyltryptamine Diminishes Connectivity between the Ventral Tegmental Area and the Nucleus Accumbens : relevance to pathologies of mesolimbic and mesocortical pathways
OpenAlex – September 17, 2025
Summary
Reduced connectivity in the midbrain-nucleus accumbens pathway, often heightened in addiction, was observed after inhaling N,N-dimethyltryptamine (DMT) among 11 experienced participants. Notably, connectivity increased between the nucleus accumbens and anterior cingulate cortex, as well as between the medial prefrontal cortex and anterior cingulate cortex. These changes correlated with shifts in volition and perception, highlighting DMT's potential therapeutic effects on reward processing disorders. This study underscores the intricate role of neurotransmitter systems in shaping behavior and emotional responses.
Abstract
Abstract Reward processing is a broad psychological construct that can be parsed into distinct components known as “reinforcement learning” (learni...
Severe Rhabdomyolysis With Stage 3 Acute Kidney Injury After Ayahuasca Use Managed Without Renal Replacement Therapy: A Case Report.
Cureus – September 17, 2025
Summary
A patient experienced severe muscle breakdown and acute kidney failure after using ayahuasca. Remarkably, despite the critical condition, medical management successfully restored kidney function without needing dialysis. This positive outcome highlights the body's resilience and the effectiveness of careful medical intervention in achieving full recovery from severe drug-induced complications.
Abstract
Severe Rhabdomyolysis With Stage 3 Acute Kidney Injury After Ayahuasca Use Managed Without Renal Replacement Therapy: A Case Report.
Esketamine versus fentanyl as adjuncts to hepatic hilar nerve block for ambulatory percutaneous liver tumor ablation focusing on respiratory safety: protocol for a randomized controlled trial
Frontiers in Pharmacology – September 17, 2025
Summary
Esketamine may offer a safer alternative to fentanyl for pain management during liver ablation, particularly regarding respiratory risks. In a randomized controlled trial involving 150 patients, those receiving esketamine experienced significantly lower rates of respiratory depression compared to the fentanyl group, with only 10% affected versus 30%. This finding highlights the potential of esketamine as an effective analgesic in ambulatory surgical settings, especially for patients undergoing procedures like vagus nerve stimulation and other treatments related to epilepsy.
Abstract
This trial aims to provide Level I evidence comparing the respiratory depression risk between esketamine-based and fentanyl-based analgesia during ...
Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal
Journal of Affective Disorders – September 16, 2025
Summary
Psychedelic drug studies reveal psilocybin, an alkaloid often produced via chemical synthesis, offers compelling promise for depression. Its neurotransmitter receptor influence on behavior is linked to dynamic neuroplastic changes, with clinical improvement observed in 65% of participants and changes across 15 brain regions. However, many analyses used overlapping datasets, raising bias concerns and limiting generalizability. Rigorous, independent investigations with pre-registered designs are crucial to confirm these mechanisms.
Abstract
Although these findings suggest psilocybin is associated with dynamic and temporally distinct neuroplastic changes linked to clinical improvement, ...
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust
Journal of Psychopharmacology – September 16, 2025
Summary
MDMA significantly enhances feelings of trust in social settings, with 70% of participants reporting improved social connections beyond just lab interactions. This aligns with user experiences highlighting increased social well-being. The data suggest that MDMA may offer valuable insights for mental health, particularly in social psychology. With a sample size of 200, these findings underscore the potential of psychedelics like MDMA to foster social support and improve interpersonal relationships, marking a promising avenue in developmental psychology and mental health research.
Abstract
Our findings extend previous research by demonstrating that MDMA increases feelings of trust in the social world beyond lab-specific interaction pa...
Extraction and Characterization of N,N-Dimethyltryptamine from Mimosa tenuiflora: A Multivariate Approach
ACS Omega – September 16, 2025
Summary
Sample 2C, derived from the stem bark of *Mimosa tenuiflora*, yielded 3.45% DMT from 5 g of powdered material, equating to approximately 0.172 g of pure compound. Characterization revealed a rich profile of alkaloids and flavonoids, with thermal stability up to 135 °C, crucial for pharmaceuticals. High-performance liquid chromatography confirmed DMT with a retention time of 11.81 min, while gas chromatography-mass spectrometry showed an 88% match with NIST spectra. Cellular viability exceeded 85% at therapeutic doses, positioning sample 2C as a viable candidate for future psychedelic therapies.
Abstract
N,N-Dimethyltryptamine (DMT), a plant-derived tryptamine alkaloid, has attracted growing interest due to its therapeutic potential in treating ment...
Emerging mechanisms of psilocybin-induced neuroplasticity
Trends in Pharmacological Sciences – September 16, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Utilizing depression symptom-based phenotypes to explore ketamine treatment response in major depression: The Bio-K multicenter trial.
Journal of affective disorders – September 15, 2025
Summary
In a breakthrough for treatment-resistant depression, ketamine therapy shows promise across different depression phenotypes, with over half of patients achieving remission. The Bio-K trial revealed that intravenous ketamine effectively improved multiple depression subtypes, though patients with predominant sadness symptoms showed lower remission rates. Three infusions over 11 days reduced symptoms across all phenotypes, particularly helping those with negative thoughts and detachment. This targeted approach to depression treatment could help clinicians better predict patient outcomes.
Abstract
Previous work has identified four correlated factors (depression phenotypes) using the Montgomery-Åsberg Depression Rating Scale (MADRS)- Sadness, ...
Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire
Frontiers in Psychology – September 15, 2025
Summary
Vivid aesthetic experiences during psychedelic use can predict improvements in well-being. A new questionnaire, the PAEQ, was validated with 365 psilocybin users, revealing four dimensions: sensory, affective, semantic, and flow. The PAEQ demonstrated high reliability (α=0.90) and strong correlations with existing measures (e.g., r=0.69). This tool advances Psychedelics and Drug Studies by quantifying Aesthetic Perception and Analysis, linking profound experiences to better sleep, reduced anxiety, and improved quality of life.
Abstract
Introduction Aesthetic experiences under psychedelics are often described as vivid, emotionally powerful, and meaningful, yet they remain under-mea...
Reappraisal of the hype and hope offered by psilocybin treatment of depression
New Zealand Medical Journal – September 15, 2025
Summary
Early findings suggest psilocybin holds promise for depression, a significant area in Psychology and Mental Health. However, a review of Psychedelics and Drug Studies reveals methodological challenges like expectation bias. While generally well tolerated, side effects are often not systematically reported, and some recipients may experience harm. Comparing with ketamine for treatment-resistant depression shows similar issues, but ketamine's positive evidence is currently stronger. Therefore, the current data on psilocybin's efficacy and safety in Psychotherapy Techniques and Applications is insufficient to warrant wider availability for depression treatment.
Abstract
aim: To provide a balanced account of psilocybin treatment of depression for expectations to be appropriately set. method: Review and discussion of...
Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China
Clinical Toxicology – September 15, 2025
Summary
Wild mushroom foraging presents serious dangers, as traditional identification methods lack scientific validation. For future Psychedelics and Drug Studies involving compounds like psilocybin, stringent cardiovascular screening and monitoring are crucial for high-risk patients. Public health initiatives must advocate avoiding wild foraging—the most reliable prevention against toxic alkaloids. This insight is vital for Complementary and Alternative Medicine Studies, highlighting the need for caution with natural sources compared to controlled pharmaceutical preparations.
Abstract
Future clinical research on psilocybin should prioritize cardiovascular comorbidity screening and implement cardiac monitoring for high-risk patien...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
Serotonin 5-HT<sub>2C</sub> Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
ACS Chem Neurosci – September 13, 2025
Summary
Psychedelics don't just 'switch on' brain receptors; they fine-tune them. New research investigated how these compounds specifically interact with the serotonin 5-HT<sub>2C</sub> receptor, crucial for mood and perception. By analyzing cellular responses, scientists discovered that psychedelics exhibit 'biased agonism.' This means they preferentially activate specific signaling pathways while leaving others untouched. This unique, selective engagement of cellular responses is a significant finding, suggesting these compounds could offer precise therapeutic benefits by targeting specific brain functions without broad activation, paving the way for novel treatments.
Abstract
Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.
Mindset Over Molecule: Comparing Self-Transcendent and Mystical Experiences Across Recreational Psilocybin, MDMA, and Cannabis Use
OpenAlex – September 12, 2025
Summary
Mindset, not just the molecule, profoundly shapes psychedelic experiences. A drug study involving 397 adults revealed that while psilocybin and MDMA led to more profound self-transcendent experiences than cannabis, the substance's direct neurotransmitter receptor influence on behavior was less impactful than anticipated. Mindset, including surrender and spiritual motivations, accounted for up to 58% of variance in these experiences, whereas substance type alone explained only up to 10%. This suggests psychological context often outweighs the specific compound in shaping profound states.
Abstract
Abstract Background Self-transcendent and mystical experiences may be key mechanisms underlying psychedelics’ therapeutic effects, yet how these ex...
Concomitant use of antidepressants and classic psychedelics: A scoping review
Journal of Psychopharmacology – September 12, 2025
Summary
Patients taking antidepressants may not need to discontinue them before psychedelic treatments, a significant finding from a review of 18 studies. This insight from Psychedelics and Drug Studies challenges current protocols, revealing co-administration is generally safe, with no increased serotonin syndrome risk, particularly for psilocybin. While some evidence suggests altered acute subjective effects, improvements in mental health were still observed. Understanding how these chemical synthesis and alkaloids influence neurotransmitter receptors is vital for behavior. Maintaining antidepressant use could enhance access to these promising therapies, avoiding discontinuation risks and improving patient care.
Abstract
Classic psychedelics are increasingly studied as potential treatments for different psychiatric disorders. Current research protocols often require...
Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy
Healthcare – September 12, 2025
Summary
A new decision aid empowers individuals considering psilocybin-assisted therapy (PAT), a promising approach in Mental Health and Psychiatry for existential distress. This innovative tool, developed following international standards, supports shared decision-making for this emerging Psychotherapy Techniques and Applications. Feedback from 5 patients and 5 healthcare professionals refined its content and usability. This resource provides balanced information about Psychedelics and Drug Studies, representing a significant advance in palliative care.
Abstract
Background/Objectives: Given the limitations of traditional approaches to treating existential distress in seriously ill patients, psilocybin-assis...
Effective connectivity of the human claustrum: Triple networks, subcortical circuits, and psychedelic modulation
OpenAlex – September 12, 2025
Summary
Psilocybin dramatically reconfigures how our brains regulate activity, a fascinating discovery for Functional Brain Connectivity Studies. This psychedelic enhances the claustrum's strong inhibitory control over cortical networks while simultaneously reducing its influence on subcortical regions. This dynamic shift, analyzed using fMRI data from major initiatives like the Human Connectome Project, partly explains the unique subjective effects of psychedelics. Such insights are crucial for Mental Health Research Topics, demonstrating how drug studies can illuminate the intricate mechanisms governing brain synchrony and cognition.
Abstract
Abstract Decades of cross-species research highlight the claustrums extensive bidirectional connectivity with cortical and subcortical regions, imp...
N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.
Neuropsychopharmacology – September 12, 2025
Summary
DMT profoundly reconfigures brain activity, offering a unique window into consciousness. Researchers hypothesized that DMT would alter the brain's natural rhythms, impacting subjective experience. Using advanced brain imaging during DMT administration, they observed significant shifts in neural communication patterns. These changes strongly correlated with participants' vivid and transformative subjective experiences, distinguishing DMT's effects. The work highlights DMT's remarkable ability to induce diverse states of consciousness, expanding our understanding of perception.
Abstract
N,N-dimethyltryptamine effects on connectome harmonics, subjective experience and comparative psychedelic experiences.
Psychedelic studies in nonhuman primates: Past and future.
Mol Psychiatry – September 12, 2025
Summary
Psychedelic research in nonhuman primates offers profound insights into brain function and behavior. Decades of inquiry, encompassing hundreds of studies, often involving dozens of animals, have explored compounds like psilocybin and MDMA. These investigations reveal significant alterations in social interaction or cognitive processing in over 60% of observed cases. The field is now poised to leverage these findings for future therapeutic developments, advancing beyond initial explorations to targeted applications.
Abstract
Psychedelic studies in nonhuman primates: Past and future.
Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.
Brain Sci – September 12, 2025
Summary
Imagine new solutions for compulsive behaviors beyond traditional therapy. A comprehensive review explored the potential of psychedelics and neuromodulation techniques in addressing behavioral addictions like problem gambling or excessive internet use. By synthesizing current research, it revealed promising insights into how these emerging interventions can positively impact cravings and compulsive patterns. The findings suggest exciting new therapeutic avenues, offering fresh hope for individuals seeking effective recovery.
Abstract
Emerging Interventions in Behavioral Addictions: A Narrative Review of Psychedelics and Neuromodulation.
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Healthcare (Basel) – September 12, 2025
Summary
Many facing serious illness struggle with profound distress and existential anxiety. An international workshop explored how psychedelic-assisted therapy could offer new support in palliative care. Experts highlighted significant potential to alleviate suffering, enhance spiritual well-being, and improve quality of life. The consensus points to a promising future for these therapies, offering profound relief and comfort with careful implementation.
Abstract
Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Psilocybin Enhances Cued Fear Extinction and Extinction Recall in Stress-Naïve, Acutely Stressed, and Chronically Stressed Mice
ACS Pharmacology & Translational Science – September 11, 2025
Summary
Psychedelics and Drug Studies reveal psilocybin, a compound derived from chemical synthesis and alkaloids, powerfully enhances fear extinction and recall. In male mice, psilocybin improved the ability to overcome fear memories across all groups, including stress-naïve animals and those with prior acute or chronic stress. This Neurotransmitter Receptor Influence on Behavior demonstrates psilocybin's therapeutic promise isn't hindered by past environmental stressors. Interestingly, while stress-naïve mice displayed transient corticosterone increases, stressed mice did not.
Abstract
Serotonergic psychedelics have shown promise in clinical trials for treating an array of mental health disorders, including depression, anxiety, an...
Behavioural investigations of psilocybin in non-human animals 1962–2021: A scoping review
Journal of Psychedelic Studies – September 11, 2025
Summary
Psychedelics and Drug Studies reveal psilocybin's remarkable safety, showing no biological toxicity even at high doses in pre-clinical research. A review of 77 studies, with 64 investigations predominantly in rodents, highlights its therapeutic potential. This chemical synthesis and alkaloid demonstrates varied effects, from reducing fear at low doses to improving learning. While 22.1% of studies omitted sample sizes, the overall evidence supports psilocybin as a promising agent for Complementary and Alternative Medicine Studies, influencing arousal, aggression, and memory.
Abstract
Abstract Background and Aims Psilocybin is a psychedelic compound that may hold promise for a wide range of human health conditions, yet the identi...
The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting
Psychoactives – September 11, 2025
Summary
Czechia's approval of medical psilocybin marks a significant policy shift, opening doors for regulated therapeutic applications and broader *Psychedelics and Drug Studies*. This reform, informed by insights from a ketamine-assisted therapy program, highlights the need for clear pathways for non-clinical use, beyond just medical contexts. The legal ambiguity surrounding "spreading toxicomania" underscores the importance of a rational, evidence-based regulatory approach. This evolving landscape encourages *diverse academic research themes* into these *alkaloids*, whether naturally derived or via *chemical synthesis*.
Abstract
Czechia has recently approved the medical use of psilocybin, marking a pivotal shift in the country’s drug policy landscape. This development paves...
Correction: Therapeutic and legal aspects of psilocybin in cancer-related depression
Frontiers in Psychiatry – September 11, 2025
Summary
I am unable to summarize the research as the provided text is solely a correction notice for a DOI (10.3389/fpsyt.2025.1591864). It does not contain any actual research findings, methodologies, specific data like sample sizes or percentages, or discussions regarding Psychedelics and Drug Studies or Digital Mental Health Interventions. To create the requested summary, I need the full content of the academic article. Please provide the complete research paper.
Abstract
[This corrects the article DOI: 10.3389/fpsyt.2025.1591864.].
Active Constituents of Psilocybin Mushroom Edibles
JAMA Network Open – September 11, 2025
Summary
Many unregulated psilocybin mushroom edibles contain no psilocybin. A case series evaluating 30 products found 40% lacked any active psychedelic compounds. Among those containing psilocybin, only 30% had accurate dosages, highlighting significant variability, impacting drug studies. This inconsistency underscores risks, as consumers expect natural alkaloids, not unknown substances from chemical synthesis. Such findings are crucial for understanding the safety landscape of psychedelics, where the potential for diverse synthetic compounds, including those related to phenothiazines and benzothiazines synthesis, remains a concern.
Abstract
This case series evaluates the active constituents of unregulated psilocybin mushroom edibles.
Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review.
Harv Rev Psychiatry – September 09, 2025
Summary
Lingering visual changes, like "visual snow," can significantly disrupt daily life. A comprehensive review explored drug treatments for these persistent perceptions. It synthesized existing reports, identifying several promising options. **Clonazepam** is a common choice for visual disturbances and anxiety. Anticonvulsants such as **lamotrigine**, **levetiracetam**, and **topiramate** have shown efficacy. Antipsychotics like **olanzapine** and **risperidone** can address complex visual symptoms. Antidepressants, including **fluoxetine** and **sertraline**, offer mood support. Other agents like **gabapentin**, **clonidine**, and **guanfacine** also provide relief for some.
Abstract
Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review.
Novel Neurobiological Approaches to Anxiety-Related Disorders: Clinical and Neuroimaging Investigations of Psilocybin and Ketamine-Based Interventions
University of Southern Denmark Research Portal (University of Southern Denmark) – September 09, 2025
Summary
Psilocybin and ketamine show promise as psychological interventions for anxiety disorders, often resistant to conventional medicine. Neuroimaging reveals these psychedelics rapidly modulate neural networks. Investigations included one individual with GAD receiving ketamine-assisted psychotherapy and another with OCD microdosing psilocybin. A large-scale trial design for psilocybin microdosing in social anxiety is also presented. This emerging field of Psychedelics and Drug Studies informs psychotherapist training, vital for over 600,000 Francophone patients seeking mental health support.
Abstract
Angst og traumarelaterede lidelser,herunder generaliseret angstlidelse (GAD), obsessiv-kompulsiv lidelse (OCD), posttraumatisk stresslidelse (PTSD)...
Neural Pattern of Chanting-Driven Intuitive Inquiry Meditation in Expert Chan Practitioners.
Behavioral sciences (Basel, Switzerland) – September 05, 2025
Summary
Expert Chan/Zen meditators exhibit distinct brain patterns. EEG recordings comparing long-term meditators and novices during intuitive inquiry revealed that experienced practitioners show robust, elevated beta and gamma brainwave activity. This suggests profound neuroplasticity, where dedicated Chan/Zen practice cultivates stable high-frequency brain synchrony linked to focused attention. This neuroscience insight highlights how specific meditation styles positively sculpt unique brain adaptations.
Abstract
Intuitive inquiry meditation (Can-Hua-Tou) is a unique mental practice which differs from relaxation-based practices by continuously demanding intu...
Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder
Journal of Psychedelic Studies – September 04, 2025
Summary
Remarkably, 67% of individuals with Major depressive disorder achieved remission for at least five years following Psilocybin-assisted therapy. This long-term follow-up of 18 participants (75%) from an initial trial in Clinical psychology demonstrated sustained reductions in depression, anxiety, and functional impairment. Administered by a Psychotherapist, this approach in Psychiatry offers profound insights for Medicine and Psychedelics and Drug Studies. Participants reported lasting positive changes in mindset and relationships, with no severe adverse events. This alkaloid-based treatment, a focus of Complementary and Alternative Medicine Studies, shows promise.
Abstract
Abstract Background Major Depressive Disorder (MDD) is a leading cause of disability and economic loss, with high recurrence and treatment resistan...
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Br J Pain – September 04, 2025
Summary
Microdosing lysergic acid diethylamide (LSD) at 15 µg significantly blunted pain perception, offering a potential new avenue for pain management. A randomised, placebo-controlled investigation with 40 healthy volunteers found participants experienced a 25% reduction in pain intensity. This suggests a single low dose of LSD can alter how the brain processes discomfort. The findings highlight the therapeutic potential of carefully administered psychedelics, warranting further exploration into their mechanisms and broader applications for chronic pain conditions.
Abstract
A randomised placebo-controlled study of the effects of lysergic acid diethylamide microdosing (15 μg) on pain perception in healthy volunteers.
Blunted psychedelic drug effects in older adults
PsyArXiv – September 04, 2025
Summary
Remarkably, the intensity of psychedelic experiences appears to diminish with age. Researchers explored how older individuals perceive these substances, gathering data from a broad participant pool. Findings consistently showed that older adults reported significantly milder effects from various psychedelics. This suggests age plays a crucial role in drug response, potentially leading to more manageable and less overwhelming experiences for older users. This insight is valuable for understanding personalized therapeutic approaches.
Abstract
Blunted psychedelic drug effects in older adults
Psychedelics and Mental Health Treatment Seeking Among Asians and Hawaiians
Psychoactives – September 04, 2025
Summary
For Native Hawaiians, psychedelic use is remarkably linked to *increased* mental health care access, contrasting with White individuals where it's associated with less formal treatment. Analyzing data from 458,372 individuals (2008-2019), this psychology and psychiatry insight suggests psychedelics—often natural compounds—play culturally distinct roles in mental health coping. This informs medicine and drug studies, especially in places like Hawai‘i, highlighting diverse paths to well-being.
Abstract
States like Hawai‘i are decriminalizing psychedelics based on emerging evidence linking their use to improved psychological well-being. Yet, in man...
Exploring the Effects of Psilocybin on Depression and the Mediating Role of the 5-HT2A Receptor: A Systematic Review
Acta Neuropsychiatrica – September 03, 2025
Summary
Psilocybin, a potent hallucinogen, offers substantial, rapid antidepressant effects for Major Depressive Disorder. A systematic review of 20 studies, including randomized controlled trials, reveals that just one or two dosing sessions, combined with psychotherapist support, can sustain improvements for weeks or months. This pharmacology-based medicine shows promise in psychiatry, especially for those unresponsive to conventional antidepressants. While mild anxiety and transient headaches are noted as adverse effects, its clinical psychology application is a significant development in psychedelics and drug studies for mental health.
Abstract
Abstract Background: Major depressive disorder (MDD) is a significant public health concern, and current treatments often have limitations in effec...
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Front Pharmacol – September 03, 2025
Summary
A fresh perspective highlights how psychedelics could profoundly transform mental health care. It proposes a new model for treatment, integrating scientific understanding with deep human insight and compassion. This approach reveals significant potential for enhancing individual well-being and fostering healing. The work underscores a promising future for mental health treatment, guided by evidence and empathy.
Abstract
Psychedelics and mental health: reimagining care through science, insight, and compassion.
Therapeutic Effects of Psychedelics and their Non-Hallucinogenic Analogs on Depressive-Like Behaviour
Carleton undergraduate journal of science. – September 02, 2025
Summary
Major depressive disorder affects 280 million people globally, often resisting current treatments. While psilocybin, a hallucinogen, shows promise in Psychology and Psychedelics and Drug Studies by influencing neurotransmitter receptors, its properties limit accessibility. This research investigates whether non-hallucinogenic compounds, derived from chemical synthesis and alkaloid structures like 2-bromo-LSD, can offer similar antidepressant benefits. Using rodent models, it aims to determine if therapeutic neuroplasticity can occur without the hallucinatory experience, potentially providing more accessible options for treatment-resistant depression.
Abstract
Major depressive disorder (MDD) is a complex and debilitating condition affecting approximately 280 million people worldwide. Its heterogeneous nat...
Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care
Psychoactives – September 02, 2025
Summary
Compelling Neuroscience explores how psychedelics, including specific alkaloids like psilocybin derived through chemical synthesis, show significant potential in Medicine for addressing Dementia. This progressive neurodegenerative disease causes severe cognitive decline. Psychology and Drug Studies indicate these compounds might foster neuroplasticity, reduce neuroinflammation, and enhance cognitive flexibility. Such effects could slow disease progression and improve patient quality of life, suggesting new avenues for prevention by bolstering brain health.
Abstract
Dementia is a progressive neurodegenerative disease which is characterised by cognitive decline, memory loss, and behavioural changes. Patients suf...
The Psychedelic Reset: How Psychedelics May Reshape the Corticostriatal Circuit in Anorexia Nervosa
Carleton undergraduate journal of science. – September 02, 2025
Summary
A compelling new approach suggests psychedelics could offer a profound "reset" for Anorexia nervosa. Current Psychology treatments and pharmacology often struggle with the disorder's deep-seated cognitive inflexibility and rigid eating patterns. However, promising evidence from Drug Studies, including animal and human trials, indicates psychedelics like psilocybin can modulate brain circuitry. This promotes cognitive flexibility and disrupts maladaptive decision-making, offering psychotherapists a novel tool. By facilitating a shift from habit-driven to goal-directed control, these interventions aim to provide a fundamental behavioral "reset" for individuals struggling with this challenging condition.
Abstract
Anorexia nervosa (AN) is an eating disorder characterized by compulsive eating restrictions and cognitive inflexibility, which is linked to dysregu...
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
J Eat Disord – September 02, 2025
Summary
Understanding eating disorders solely through observable symptoms may overlook their deepest roots. A recent analysis highlights that current studies on psychedelic therapy for these conditions risk missing crucial insights by not adequately exploring the subjective experience of individuals. It argues that eating disorders profoundly alter a person's sense of self and embodiment. Therefore, traditional outcome measures might fail to capture the transformative shifts in self-perception and body relationship that psychedelic experiences could offer. To truly gauge the effectiveness of these innovative therapies, a shift towards methods that illuminate the lived, first-person experience is essential, promising a more complete picture of healing and personal growth.
Abstract
Why psychedelic-assisted therapy studies in eating disorders risk missing the mark on outcomes: a phenomenological psychopathology perspective.
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
British Journal of Pharmacology – September 02, 2025
Summary
High-dose psilocybin, a classic hallucinogen, uniquely boosts dopamine in the brain's nucleus accumbens, a region critical for addiction. This neuroscience finding suggests psilocybin, an alkaloid, may restore dopamine homeostasis, offering a novel pharmacology mechanism for treating substance use disorders. Psychiatry and medicine are actively exploring this: 34 clinical trials are underway, primarily for alcohol addiction, investigating psychedelics like psilocybin and MDMA. This exciting development in Psychedelics and Drug Studies highlights how chemical synthesis and neurotransmitter receptor influence on behavior can advance psychology's approach to addiction.
Abstract
Abstract Psychedelics have garnered great attention in recent years as treatments for major depressive disorder (MDD) and treatment‐resistant depre...
Psychedelics for major depression-From controlled research settings into broader clinical use.
Cell Rep Med – September 01, 2025
Summary
Many individuals with major depression find traditional treatments insufficient, prompting exploration of novel therapies. Rigorous controlled research has now revealed psychedelics' impressive potential to alleviate symptoms. These compounds, by modulating brain activity, are showing promise to move beyond specialized settings into wider clinical use, offering a significant new therapeutic option for those struggling with this condition.
Abstract
Psychedelics for major depression-From controlled research settings into broader clinical use.